

IN THE CLAIMS:

Please amend the claims as follows:

Cancel Claim 1 without prejudice, and replace it with new Claims 25 to 30 as follows:

25. (new) A method for the administration of a substance to a human subject, comprising delivering the substance into the intradermal compartment of the human subject's skin, so that the substance is distributed systemically.

26. (new) A method for the administration of a substance to a human subject comprising delivering the substance into the intradermal compartment of the human subject's skin in an amount and at a rate sufficient to deliver the substance systemically.

27. (new) A method for the administration of a substance to a human subject, comprising delivering the substance into the intradermal compartment of the human subject's skin, so that a clinically useful amount of the substance is distributed systemically.

Sub B3
A!
~~28. (new) A method for the administration of a substance to a human subject, comprising delivering the substance into the intradermal compartment of the human subject's skin via a needle having a length sufficient to penetrate the intradermal space and an outlet at a depth within the intradermal space so that the substance is distributed systemically.~~

29. (new) A method for the administration of a substance to a human subject, comprising delivering the substance into the intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with higher plasma levels.

30. (new) A method for the administration of a substance to a human subject, comprising delivering the substance into the intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a faster onset of detectable plasma levels.

Cancel claims 8 and 9 without prejudice.

Amend Claims 2-7, and 10-16 to read as follows:

2. (Amended) The method of Claim 28, wherein the needle is selected from the group consisting of microneedles, catheter needles, and injection needles.

3. (Amended) The method of Claim 28, wherein a single needle is inserted.

4. (Amended) The method of Claim 28, wherein multiple needles are inserted.

R2 Sub 1
5. (Amended) The method of any of Claims 25-30, wherein the substance is a liquid delivered by pressure directly on the liquid.

6. (Amended) The method of any of Claims 25-30, wherein a hormone is delivered.

7. (Amended) The method of Claim 6, wherein the hormone is selected from the group consisting of insulin and PTH.

10. (Amended) The method of Claim 28, wherein the needle is about 300 μ m to 2 mm long.

11. (Amended) The method of Claim 28, wherein the needle is about 500 μ m to 1 mm long.

R3
12. (Amended) The method of Claim 28, wherein the outlet is at a depth of about 250 μ m to 2 mm when the needle is inserted.

13. (Amended) The method of Claim 28, wherein the outlet is at a depth of about 750 μ m to 1.5 mm when the needle is inserted.